159 related articles for article (PubMed ID: 25120776)
1. Increased chromogranin A and neuron-specific enolase in rats with chronic nonbacterial prostatitis induced by 17-beta estradiol combined with castration.
Fan S; Hao ZY; Zhang L; Chen XG; Zhou J; Zang YF; Tai S; Liang CZ
Int J Clin Exp Pathol; 2014; 7(7):3992-9. PubMed ID: 25120776
[TBL] [Abstract][Full Text] [Related]
2. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.
Sainio M; Visakorpi T; Tolonen T; Ilvesaro J; Bova GS
Pathol Res Pract; 2018 Jun; 214(6):848-856. PubMed ID: 29728311
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin‑induced autophagy attenuates hormone‑imbalance‑induced chronic non‑bacterial prostatitis in rats via the inhibition of NLRP3 inflammasome‑mediated inflammation.
Lu J; Su Y; Chen X; Chen Y; Luo P; Lin F; Zhang J
Mol Med Rep; 2019 Jan; 19(1):221-230. PubMed ID: 30483781
[TBL] [Abstract][Full Text] [Related]
4. Qinghua decoction improves chronic nonbacterial prostatitis possibly regulating the chromogranin A/nerve growth factor/tyrosine kinase A signaling pathway mediated by inflammatory factors.
Yunpeng H; Wentao YU; Ying Z; Huazhou XU; Guoxing D; Chaoyi F
J Tradit Chin Med; 2023 Aug; 43(4):695-703. PubMed ID: 37454254
[TBL] [Abstract][Full Text] [Related]
5. Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer.
Ather MH; Abbas F; Faruqui N; Israr M; Pervez S
BMC Urol; 2008 Dec; 8():21. PubMed ID: 19115997
[TBL] [Abstract][Full Text] [Related]
6. Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer.
Fan L; Wang Y; Chi C; Pan J; Xun S; Xin Z; Hu J; Zhou L; Dong B; Xue W
BJU Int; 2017 Aug; 120(2):226-232. PubMed ID: 28107595
[TBL] [Abstract][Full Text] [Related]
7. Secretagogin is a new neuroendocrine marker in the human prostate.
Adolf K; Wagner L; Bergh A; Stattin P; Ottosen P; Borre M; Birkenkamp-Demtröder K; Orntoft TF; Tørring N
Prostate; 2007 Apr; 67(5):472-84. PubMed ID: 17285592
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer.
Szarvas T; Csizmarik A; Fazekas T; Hüttl A; Nyirády P; Hadaschik B; Grünwald V; Püllen L; Jurányi Z; Kocsis Z; Shariat SF; Sevcenco S; Maj-Hes A; Kramer G
BJU Int; 2021 Jan; 127(1):44-55. PubMed ID: 32314509
[TBL] [Abstract][Full Text] [Related]
9. The anti-inflammatory effect of montelukast, a cysteinyl leukotriene receptor-1 antagonist, against estradiol-induced nonbacterial inflammation in the rat prostate.
Said MM; Bosland MC
Naunyn Schmiedebergs Arch Pharmacol; 2017 Feb; 390(2):197-205. PubMed ID: 27909742
[TBL] [Abstract][Full Text] [Related]
10. Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy.
Heck MM; Thaler MA; Schmid SC; Seitz AK; Tauber R; Kübler H; Maurer T; Thalgott M; Hatzichristodoulou G; Höppner M; Nawroth R; Luppa PB; Gschwend JE; Retz M
BJU Int; 2017 Jan; 119(1):30-37. PubMed ID: 27037533
[TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings?
Angelsen A; Syversen U; Haugen OA; Stridsberg M; Mjølnerød OK; Waldum HL
Prostate; 1997 Jan; 30(1):1-6. PubMed ID: 9018329
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine differentiation in colorectal carcinomas.
Syversen U; Halvorsen T; Mårvik R; Waldum HL
Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):667-74. PubMed ID: 8590163
[TBL] [Abstract][Full Text] [Related]
14. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.
Nobels FR; Kwekkeboom DJ; Coopmans W; Schoenmakers CH; Lindemans J; De Herder WW; Krenning EP; Bouillon R; Lamberts SW
J Clin Endocrinol Metab; 1997 Aug; 82(8):2622-8. PubMed ID: 9253344
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment Levels of Chromogranin A and Neuron-specific Enolase in Patients With Gastroenteropancreatic Neuroendocrine Neoplasia.
Kečkéš Š; Palaj J; Waczulíková I; Dyttert D; Mojtová E; Kováč G; Durdík Š
In Vivo; 2021; 35(5):2863-2868. PubMed ID: 34410979
[TBL] [Abstract][Full Text] [Related]
16. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.
Baudin E; Gigliotti A; Ducreux M; Ropers J; Comoy E; Sabourin JC; Bidart JM; Cailleux AF; Bonacci R; Ruffié P; Schlumberger M
Br J Cancer; 1998 Oct; 78(8):1102-7. PubMed ID: 9792158
[TBL] [Abstract][Full Text] [Related]
17. Anti-inflammatory and anti-hyperplastic effect of Bazhengsan in a male rat model of chronic nonbacterial prostatitis.
Xiong Y; Zhou L; Qiu X; Miao C
J Pharmacol Sci; 2019 Mar; 139(3):201-208. PubMed ID: 30773299
[TBL] [Abstract][Full Text] [Related]
18. Neuroendocrine cells in prostate cancer correlate with poor outcomes: a systematic review and meta-analysis.
Kannan A; Clouston D; Frydenberg M; Ilic D; Karim MN; Evans SM; Toivanen R; Risbridger GP; Taylor RA
BJU Int; 2022 Oct; 130(4):420-433. PubMed ID: 34784097
[TBL] [Abstract][Full Text] [Related]
19. Re: Biological variation of neuroendocrine tumor markers chromogranin A and neuron-specific enolase.
Dittadi R; Gion M
Clin Biochem; 2013 Aug; 46(12):1145. PubMed ID: 23608355
[No Abstract] [Full Text] [Related]
20. Selected markers (chromogranin A, neuron-specific enolase, synaptophysin, protein gene product 9.5) in diagnosis and prognosis of neuroendocrine pulmonary tumours.
Kasprzak A; Zabel M; Biczysko W
Pol J Pathol; 2007; 58(1):23-33. PubMed ID: 17585539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
